tert-butyl L-alanyl-L-alaninate hydrochloride | 60417-38-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl L-alanyl-L-alaninate hydrochloride
• 英文别名: (S)-tert-butyl 2-((S)-2-aminopropanamido)propanoate hydrochloride；tert-butyl (2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoate;hydrochloride
• CAS: 60417-38-1
• 化学式: C₁₀H₂₀N₂O₃*ClH
• 分子量: 252.741
• InChiKey: OVTLRMKNRNPEBY-LEUCUCNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  81.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-((R)-α-carboxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 、 tert-butyl L-alanyl-L-alaninate hydrochloride 在 N-甲基吗啉 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以45%的产率得到1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-{N-[(S)-1-(t-butoxycarbonyl)ethyl]carbamoyl}ethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine
  参考文献：
  名称：

  BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA

  摘要：

  公开号：

  EP1427423B9

文献信息

• Catalytic Peptide Synthesis: Amidation of <i>N</i>-Hydroxyimino Esters
  作者：Wataru Muramatsu、Hiroaki Tsuji、Hisashi Yamamoto

  DOI：10.1021/acscatal.7b04244

  日期：2018.3.2

  A catalytic method for the formation of amide bonds was developed in which the amidation of N-hydroxyimino esters with a broad range of amino acid tert-butyl esters is promoted by a niobium catalyst in the absence of solvent. Contrary to the predominant protocol based on reagent control commonly applied to amidation reactions, this study provides insight into an approach based on substrate control

  开发了一种形成酰胺键的催化方法，其中酰胺化具有广泛氨基酸范围的N-羟基亚氨基酯在不存在溶剂的情况下，铌催化剂可促进生成丁酸酯。与通常用于酰胺化反应的基于试剂控制的主要方案相反，本研究为基于底物控制的方法提供了见识。该系统除了具有高原子效率和无外消旋作用外，还以高收率提供了相应的酰胺。该系统的优点在于，在未活化的酯存在下，路易斯酸催化化学选择性地进行。此外，在简单的氢化条件下，所得的酰胺易于以高非对映选择性被转化为其相应的二肽和三肽。
• [EN] BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA<br/>[FR] DERIVES DE BENZOTHIAZEPINE ET DE BENZOTHIADIAZEPINE PRESENTANT UNE ACTIVITE INHIBITRICE DU TRANSPORT DES ACIDES BILIAIRES ILEAUX (IBAT), DESTINES AU TRAITEMENT DE L'HYPERLIPIDEMIE
  申请人：ASTRAZENECA AB

  公开号：WO2003022286A1

  公开（公告）日：2003-03-20

  The present invention relates to compounds of formula (I) wherein R?v, R1, R2, Rx, Ry, M, Rz, v, R3, R4, R5 and R6¿ are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本发明涉及式(I)化合物，其中Rv，R1，R2，Rx，Ry，M，Rz，v，R3，R4，R5和R6是如定义的；其药学上可接受的盐，溶剂，该类盐的溶剂和其前药的用途作为回肠胆酸转运（IBAT）抑制剂，用于治疗高脂血症。还描述了它们的制造过程和含有它们的制药组合物。
• Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
  申请人：Starke Ingemar

  公开号：US20050038009A1

  公开（公告）日：2005-02-17

  The present invention relates to compounds of formula (I) wherein R v , R 1 , R 2 , R x , R y , M, R z , v, R 3 , R 4 , R 5 and R 6 are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本发明涉及式(I)化合物，其中Rv、R1、R2、Rx、Ry、M、Rz、v、R3、R4、R5和R6的定义如下；药学上可接受的盐、溶剂、这些盐的溶剂和其前药，并且它们的用途是作为追随性胆汁酸转运（IBAT）抑制剂，用于治疗高脂血症。还描述了它们的制造过程和包含它们的制药组合物。
• MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES
  申请人：Saulnier Mark G.

  公开号：US20130281657A1

  公开（公告）日：2013-10-24

  The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.

  本发明提供了制备大环化合物的方法，包括稳定大环化肽（MSPs）。根据适当取代的2-氨基噻唑-5-基甲醇生成的亚胺喹啉甲烷型中间体的亲核捕获，制备大环和MSP。在大环的情况下，首选亲核试剂可以从富电子芳香基团中选择，在MSP的情况下，至少有一种氨基酸包含富电子芳香基团。此外，该概念可以扩展到取代噻唑的其他相关5-成员杂环系统，例如咪唑或噁唑。生成相应的亚胺喹啉甲烷型中间体的条件可能与用于2-氨基噻唑-5-基甲醇的条件相似或不同。
• Macrocycles and macrocycle stabilized peptides
  申请人：Saulnier Mark G.

  公开号：US09169295B2

  公开（公告）日：2015-10-27

  The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.

  该发明提供了制备大环化合物的方法，包括大环稳定的肽（MSPs）。通过从适当取代的2-氨基噻唑-5-基甲醇生成的亚胺喹啉甲亚型中间体的亲核捕获来制备大环和MSPs。在大环的情况下，优选的亲核试剂可以从富电子芳香基团中选择，在MSPs的情况下，至少一个氨基酸包含一个富电子芳香基团。此外，该概念可以扩展到取代噻唑的其他相关5-成员杂环系统，例如咪唑或噁唑。生成相应的亚胺喹啉甲亚型中间体的条件可以与用于2-氨基噻唑-5-基甲醇的条件相似或不同。